Abstract 282P
Background
Multiple Myeloma (MM) is second most common hematological malignancy characterized by uncontrolled proliferation of abnormal plasma cells in bone marrow. microRNAs are newly emerged nowadays for their involvement in post-transcriptional regulation of certain genes. Earlier, we reported overexpression of an extracellular matrix protein, Versican (VCAN) in MM especially in the stroma but its involvement in disease pathogenesis has not been reported yet. Hence, we studied the role of VCAN via its regulation by microRNAs on myeloma pathogenesis.
Methods
The molecular expression of VCAN was investigated in myeloma cell lines (RPMI8226 & U266). The antagomirs of microRNAs (miR-144 and miR-199) were then transfected into myeloma cells to investigate the effect on VCAN expression along with the effect on proliferation, apoptosis, migration and invasion of myeloma cells. In addition, signaling pathways affected by the inhibition of miR-144 and miR-199 were also identified. The functional regulation of VCAN by miR-144 and miR-199 was also confirmed by reporter luciferase assay in which VCAN 3’UTR was transfected to the myeloma cells.
Results
The expression of VCAN was found at minimal level in both the myeloma cells. The transfection of antagomirs of miR-144 and miR-199 significantly enhanced the transcript and protein levels of VCAN in myeloma cells. Further, myeloma cells parameters found to be altered in favor of disease progression such as cell proliferation, migration and invasion increased with simultaneous inhibition of apoptosis. In addition, antagomirs mediated upregulation of VCAN promote myeloma progression via activation of FAK/STAT3 signaling. Moreover, transfection of wild type VCAN 3’UTR resulted in significant decrease in luciferase activity which got restored by mutating the binding site of microRNAs.
Conclusions
miR-144 and mir-199 antagomirs mediated over-expression of VCAN promoted the myeloma pathogenesis in vitro with downstream activation of FAK and STAT3 signaling. These findings, therefore, affirm the translational importance of microRNAs which could be adopted as a mean for targeting VCAN and might emerge as an effective therapy for better management of MM in clinical settings in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
AIIMS, New Delhi, India.
Funding
All India Institute of Medical Sciences, Council of Scientific and Industrial Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
458P - Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC
Presenter: Martin Filipits
Session: Poster display session
Resources:
Abstract
460P - Mendelian randomization study showed no causality between metformin use and lung cancer risk
Presenter: Jiayi Shen
Session: Poster display session
Resources:
Abstract
461P - Blood trace minerals and lung cancer: A Mendelian randomization study
Presenter: Wei Xian
Session: Poster display session
Resources:
Abstract
463P - Prediction of invasiveness in lung adenocarcinoma using machine learning algorithm based on 3D-CT imaging
Presenter: Yusuke Saeki
Session: Poster display session
Resources:
Abstract
459P - Fish intake, dietary polyunsaturated fatty acids, and lung cancer: systematic review and dose-response meta-analysis of 1.7 million men and women
Presenter: Chao Cao
Session: Poster display session
Resources:
Abstract
462P - Usefulness for prevention of postoperative cerebrovascular complications in patients with lung cancer using carotid ultrasonography
Presenter: Sadanori Takeo
Session: Poster display session
Resources:
Abstract
468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
Presenter: Masahiro Tsuboi
Session: Poster display session
Resources:
Abstract
469P - Comparison of combined chemoradiotherapy regimens; Paclitaxel plus carboplatin and cisplatin plus etoposide for locally advanced non-small cell lung cancer: A randomised phase III trial
Presenter: Alper Ata
Session: Poster display session
Resources:
Abstract
472P - Integration of expression rate and absolute cell counts of PD-1+ stromal tumour-infiltrating lymphocytes: Prognostic significance in esophageal squamous cell carcinoma
Presenter: Qingkun Song
Session: Poster display session
Resources:
Abstract
467P - The free-circulating mtDNA copies number in plasma of patients with NSCLC
Presenter: Olga Bulgakova
Session: Poster display session
Resources:
Abstract